See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Pope Francis
Vatican
Catholic Church
Social Media
Artificial Intelligence
Church
IPL
Donald Trump
NFL
Trade War
Tariffs
Published • loading... • Updated

Sacituzumab Govitecan/Pembrolizumab Yields Significant PFS Improvement in TNBC

Summary by cancernetwork.com
Sacituzumab govitecan plus pembrolizumab showed a trend for improved overall survival vs standard of care in patients with untreated PD-L1–positive TNBC.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All
Left
Center
Right
cancernetwork.comcancernetwork.com

Sacituzumab Govitecan/Pembrolizumab Yields Significant PFS Improvement in TNBC

Sacituzumab govitecan plus pembrolizumab showed a trend for improved overall survival vs standard of care in patients with untreated PD-L1–positive TNBC.

Read Full Article
targetedonc.comtargetedonc.com

Sacituzumab Govitecan Plus Pembrolizumab Improves PFS in PD-L1+ TNBC

ASCENT-04 data showed sacituzumab govitecan plus pembrolizumab improved progression-free survival in PD-L1+ metastatic triple-negative breast cancer.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

targetedonc.com broke the news in on Monday, April 21, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal